Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How did I get my own unique set of fingerprints? - 221 Things You Ought to Never Tell Your Childless Companion
- 3All that You Really want to Be familiar with Dental Inserts Facilities
- 4The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program
- 5Parents who delay baby's first vaccines also likely to skip measles shots
- Mossad unveils network of Hamas terror infrastructure across Europe
- Divorce filings, feuds and legal trouble: The 'Mormon Wives' drama keeps piling up
- Instructions to Pick the Right Dental Expert for Teeth Substitution
- NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis
- The most effective method to Arrange a Higher Medical caretaker Pay During Your Next New employee screening
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- IDF begins destroying homes used by Hezbollah as forces move deeper into southern Lebanon
- IAF intercepts over 90% of drones launched by Iran, Hezbollah during Operation Roaring Lion
